Narasimhan Mani - 19 Sep 2024 Form 4 Insider Report for Scienture Holdings, Inc. (SCNX)

Role
President & Co-CEO, Director
Signature
/s/ Kate L. Bechen, as attorney-in-fact for Narasimhan Mani
Issuer symbol
SCNX
Transactions as of
19 Sep 2024
Net transactions value
$0
Form type
4
Filing time
12 Mar 2026, 21:32:38 UTC
Previous filing
05 Aug 2024
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Narasimhan Mani filed Form 4 for Scienture Holdings, Inc. (SCNX) on 12 Mar 2026."

Quick Takeaways

  • This page summarizes Narasimhan Mani's Form 4 filing for Scienture Holdings, Inc. (SCNX).
  • 6 reported transactions and 1 derivative row are listed below.
  • Filing timestamp: 12 Mar 2026, 21:32.

What Changed

  • Previous filing in this sequence was filed on 05 Aug 2024.
  • Current net transaction value: $0.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Narasimhan Mani President & Co-CEO, Director C/O SCIENTURE HOLDINGS, INC., 20 AUSTIN BLVD., COMMACK /s/ Kate L. Bechen, as attorney-in-fact for Narasimhan Mani 12 Mar 2026 0002031317

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SCNX Common Stock, par value $0.00001 Conversion of derivative security +1,357,538 +2342% 1,415,515 19 Sep 2024 By Srivatsav, LLC F1, F2
transaction SCNX Common Stock, par value $0.00001 Other -20,000 -1.4% $0.000000* 1,395,515 10 Mar 2025 By Srivatsav, LLC F2, F3
transaction SCNX Common Stock, par value $0.00001 Award +750,000 $0.000000* 750,000 14 Apr 2025 Direct F4
transaction SCNX Common Stock, par value $0.00001 Award +300,000 +40% $0.000000* 1,050,000 01 Oct 2025 Direct F5
transaction SCNX Common Stock, par value $0.00001 Award +500,000 +48% $0.000000* 1,550,000 20 Feb 2026 Direct F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SCNX Series X Non-Voting Convertible Preferred Stock Conversion of derivative security -1,357,538 -100% $0.000000* 0 19 Sep 2024 Common Stock, par value $0.00001 1,357,538 By Srivatsav, LLC F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares of the Series X Non-Voting Convertible Preferred Stock, par value $0.00001 per share (the "Series X Preferred Stock"), of Scienture Holdings, Inc. (the "Issuer"), formerly known as TRxADE HEALTH, INC., automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on the twentieth calendar day following the Issuer's mailing of an information statement on Schedule 14C in connection with the closing of the Issuer's previously announced acquisition of Scienture, Inc. on July 25, 2024 pursuant to an Agreement and Plan of Merger. The Series X Preferred Stock had no expiration date.
F2 These securities are owned directly by Srivatsav, LLC ("Srivatsav"). As the Managing Member of Srivatsav, Dr. Narasimhan Mani may be deemed to be the indirect beneficial owner of securities held by Srivatsav. Dr. Mani disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F3 These shares of Common Stock were transferred by Srivatsav to a designee of NVK Finance, LLC (the "Lender") as consideration for the Lender's consent to certain transactions contemplated by that certain First Amendment to Loan and Security Agreement, dated November 22, 2024, entered into by the Issuer, the Lender, Dr. Mani, and certain other parties thereto.
F4 These shares of restricted Common Stock ("Restricted Shares") vest in two equal annual installments beginning on April 14, 2026.
F5 These Restricted Shares vest in two equal annual installments beginning on October 1, 2026.
F6 On February 20, 2026, the Compensation Committee of the Issuer's Board of Directors approved the award of these Restricted Shares as a discretionary stock bonus for performance in 2025. The Restricted Shares will be issued in three tranches of 166,666 shares on June 1, 2026, 166,667 shares on September 1, 2026, and 166,667 shares on December 1, 2026. Each tranche of Restricted Shares will vest three years following its respective issuance date.

Sponsored